We have developed an analytical workflow for the determination of the epitopes of protein drug ADAs from a minimal amount of patient plasma and used it for the determination of the anti-rhGAA ADA epitopes from Pompe-disease patient plasma samples. Here, AGPS is linked to glycogen storage disease II.